Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.39 |
| ▸ | NPR3 | P17342 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7973604 | 1.00 | CTSK (0.40) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL22787789 | 1.00 | CTSK (0.40) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL16684109 | 0.88 | CA1 (0.37) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL22424760 | 0.87 | CTSS (0.42) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL10241566 | 0.85 | CA12 (0.35) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL10241539 | 0.85 | CA12 (0.35) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL3958726 | 0.84 | CTSK (0.36) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL15173530 | 0.83 | CTSK (0.40) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL15173531 | 0.83 | CTSK (0.40) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL23901493 | 0.82 | CA12 (0.33) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4696316-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260042740-A1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4688789-A1 | MACROCYCLIC RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688791-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688790-A1 | MACROCYCLIC RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4054719-B1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260028353-A1 | MACROCYCLIC RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2026-01-29 | — | — | US | disclosed |
| US-20250388598-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-12-25 | — | — | US | disclosed |
| US-20250368661-A1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4656201-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| WO-2022060583-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2022-03-24 | — | — | WO | disclosed |
| CN-113498342-A | Compounds involved in synergistic binding and uses thereof | 锐新医药公司 | 2021-10-12 | — | — | CN | disclosed |
| US-20210130369-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| US-20210130326-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| WO-2020181688-A1 | PREPARATION METHOD FOR DRUG-LINKER MC-MMAF USED AS ANTIBODY-DRUG CONJUGATE, AND INTERMEDIATE THEREOF | 联宁（苏州）生物制药有限公司 | 2020-09-17 | — | — | WO | disclosed |
| WO-2020132597-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | Revolution Medicines, Inc. | 2020-06-25 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-6271252-B1 | ASTHMA THERAPY, ANTIALLERGENS, ANTIINFLAMMATORY AGENTS,MULTIPLE SCLEROSIS, AUTOIMMUNE DISEASES | MERCK & CO., INC. | 2001-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368661-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CTSK 1458/4885CTSS 1023/4885CA1 4685/4885 |
| US-20260042740-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CTSK 1477/4885CTSS 1373/4885CA1 3178/4885 |
| US-20260028353-A1 | MACROCYCLIC RAS INHIBITORS | KRAS, NRAS, HRAS | CTSK 1455/4885CTSS 1543/4885CA1 3379/4885 |
| US-20200197391-A1 | COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF | KRAS, NRAS, HRAS | CTSK 2801/4885CTSS 2805/4885CA1 4640/4885 |
| US-20210130326-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CTSK 1458/4885CTSS 1023/4885CA1 4685/4885 |
| US-20210130303-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CTSK 1458/4885CTSS 1023/4885CA1 4685/4885 |
| US-20250388598-A1 | RAS INHIBITORS | KRAS, NRAS, G3BP2 | CTSK 2221/4885CTSS 1701/4885CA1 4803/4885 |
| US-20210130369-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CTSK 1458/4885CTSS 1023/4885CA1 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.